PDF herunterladen
Zentralbl Chir 2013; 138(S 02): e86-e94
DOI: 10.1055/s-0032-1328098
Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Management bei katheterassoziierter Armvenenthrombose

Management of Catheter-Related Upper Extremity Deep Vein Thrombosis
B. Linnemann
Schwerpunkt Angiologie/Hämostaseologie, Klinikum der Goethe-Universität Frankfurt am Main, Deutschland
,
E. Lindhoff-Last
Schwerpunkt Angiologie/Hämostaseologie, Klinikum der Goethe-Universität Frankfurt am Main, Deutschland
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
10. April 2013 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Zentralvenöse Zugangswege werden mit zunehmender Häufigkeit in der Therapie akuter und chronischer Erkrankungen eingesetzt. Katheterassoziierte Thrombosen und thrombotische Katheterokklusionen sind häufige Komplikationen, insbesondere wenn Portkatheter für langfristige Therapien eingesetzt werden. Diese Übersichtsarbeit beschäftigt sich vorzugsweise mit dem optimalen Umgang mit diesen Komplikationen. Risikofaktoren für katheterassoziierte Thrombosen sind eine Fehllage der Katheterspitze, eine maligne Grunderkrankung und eine Hyperkoagulabilität. Thrombosen treten vor allem im Zusammenhang mit Katheterinfektionen auf; Lungenembolien in der Akutphase und ein postthrombotisches Syndrom im Langzeitverlauf kommen ebenfalls vor. Am häufigsten wird heutzutage die farbkodierte Duplexsonografie zur Diagnose katheterassoziierter Thrombosen eingesetzt, die am häufigsten die V. subclavia betreffen. Die Therapie besteht in der Regel in der Einleitung einer volltherapeutischen Antikoagulation, die für eine Dauer von mindestens 3 Monaten beziehungsweise länger durchgeführt wird, wenn der Katheter für die Fortführung einer Therapie belassen wird. Für die Prävention katheterassoziierter Thrombosen ist die korrekte Lage der Katheterspitze in der proximalen V. cava superior von Bedeutung. Regelmäßiges Spülen des Katheters mit Kochsalzlösung oder unfraktioniertem Heparin beugt einer Katheterokklusion vor. Der primärpräventive Einsatz von Antikoagulanzien zur Verhinderung von Thrombosen kann zum jetzigen Zeitpunkt nicht empfohlen werden.

Abstract

Central venous catheters (CVCs) are important tools in the care of patients with acute or chronic diseases, but catheter-related thrombosis and thrombotic occlusions are frequent complications, especially if CVCs are implanted for long-term use. In this review we focus on the management of these complications. Risk factors for catheter-related thrombosis include dislocation of the catheter tip, the presence of malignant disease and hypercoagulability. Catheter-related thrombosis is associated with catheter infection, pulmonary embolism and post-thrombotic syndrome. Catheter-related thromboses which most frequently involve the subclavian vein are usually diagnosed by duplex ultrasound examination and treated with anticoagulation therapy for a minimum of three months or longer if the catheter is left in place. Prevention of catheter-related thrombotic complications includes proper positioning of the CVC with the catheter tip lying in the proximal superior vena cava and regular flushing of the catheter with saline solution or unfractionated heparin. The use of anticoagulants for primary prevention is currently not recommended.

Schlüsselwörter

Armvenenthrombose - Okklusion - zentralvenöser Katheter - Therapie

Key words

upper extremity deep vein thrombosis - occlusion - central venous catheter - treatment
 

  • Literatur

  • 1 Kearon C, Akl EA, Comerota AJ et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 Suppl 2: e419S-e494S
    CrossrefPubMedGoogle Scholar
  • 2 Kucher N. Deep venous thrombosis of the upper extremities. N Engl J Med 2011; 364: 861-869
    CrossrefPubMedGoogle Scholar
  • 3 Linnemann B, Meister F, Schwonberg J et al. Hereditary and acquired thrombophilia in patients with upper extremity deep-vein thrombosis. Results from the MAISTHRO registry. Thromb Haemost 2008; 100: 440-446
    PubMedGoogle Scholar
  • 4 Hingorani A, Ascher E, Marks N et al. Morbidity and mortality associated with brachial vein thrombosis. Ann Vasc Surg 2006; 20: 297-300
    CrossrefPubMedGoogle Scholar
  • 5 Munoz FJ, Mismett P, Poggio R et al. Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE Registry. Chest 2008; 133: 143-148
    CrossrefPubMedGoogle Scholar
  • 6 Flinterman LE, van Hylckama Vlieg A, Rosendaal FR et al. Recurrent thrombosis and survival after a first venous thrombosis of the upper extremities. Circulation 2004; 110: 566-572
    CrossrefPubMedGoogle Scholar
  • 7 Elman EE, Kahn SR. The post-thrombotic syndrome after upper extremity deep venous thrombosis in adults: a systemic review. Thromb Res 2006; 117: 609-614
    CrossrefPubMedGoogle Scholar
  • 8 Baskin JL, Pui C, Reiss U et al. Management of occlusion and thrombosis associated with longterm indwelling central venous catheters. Lancet 2009; 374: 159-169
    CrossrefPubMedGoogle Scholar
  • 9 Joffe HV, Kucher N, Tapson VF et al. Upper-extremity deep vein thrombosis: a prospective registry of 592 patients. Circulation 2004; 110: 1605-1611
    CrossrefPubMedGoogle Scholar
  • 10 Wilson LD, Detterbeck FC, Yahalom J. Superior vena cava syndrome with malignant causes. N Engl J Med 2007; 356: 1862-1869
    CrossrefPubMedGoogle Scholar
  • 11 Baarslag HJ, Koopman MM, Hutten BA et al. Long-term follow-up of patients with suspected deep vein thrombosis of the upper extremity: survival, risk factors and post-thrombotic syndrome. Eur J Intern Med 2004; 15: 503-507
    CrossrefPubMedGoogle Scholar
  • 12 Merminod T, Pellicciotta S, Bounameaux H. Limited usefulness of D-dimer in suspected deep vein thrombosis of the upper extremities. Blood Coagul Fibrinolysis 2006; 17: 225-226
    CrossrefPubMedGoogle Scholar
  • 13 van Rooden CJ, Tesselaar ME, Osanto S et al. Deep vein thrombosis associated with central venous catheters – a review. J Thromb Haemost 2005; 3: 2409-2419
    CrossrefPubMedGoogle Scholar
  • 14 Di Nisio M, Van Sluis GL, Bossuyt PM et al. Accuracy of diagnostic tests for clinically suspected upper extremity deep vein thrombosis: a systematic review. J Thromb Haemost 2010; 8: 684-692
    CrossrefPubMedGoogle Scholar
  • 15 Blättler W, Gerlach H, Hach-Wunderle V et al. Diagnostik und Therapie der Venenthrombose und der Lungenembolie. Interdisziplinäre S2-Leitlinie. VASA 2010; 39 Suppl 78: 1-39
    CrossrefPubMedGoogle Scholar
  • 16 Amann-Vesti B, Thalhammer C, Huck K. Kursbuch Doppler- und Duplexsonografie. 3.. Auflage. Georg Thieme Verlag: Stuttgart; 2012
    Google Scholar
  • 17 Baarslag HJ, Van Beek EJ, Reekers JA. Magnetic resonance venography in consecutive patients with suspected deep vein thrombosis of the upper extremity: initial experience. Acta Radiol 2004; 45: 38-43
    CrossrefPubMedGoogle Scholar
  • 18 Kim H, Chung JW, Park JH et al. Role of CT venography in the diagnosis and treatment of benign thoracic central venous obstruction. Korean J Radiol 2003; 4: 146-152
    CrossrefPubMedGoogle Scholar
  • 19 Shivakumar SP, Anderson DR, Couban S. Catheter-associated thrombosis in patients with malignancy. J Clin Oncol 2009; 27: 4858-4864
    CrossrefPubMedGoogle Scholar
  • 20 Luciani A, Clement O, Halimi P et al. Catheter-related upper extremity deep venous thrombosis in cancer patients: a prospective study based on Doppler US. Radiology 2001; 220: 655-660
    CrossrefPubMedGoogle Scholar
  • 21 Ce Cicco M, Matovic M, Balestreri L et al. Central venous thrombosis: an early and frequent complication in cancer patients bearing long-term silastic catheter. A prospective study. Thromb Res 1997; 86: 101-113
    CrossrefPubMedGoogle Scholar
  • 22 Gould JR, Carloss HW, Skinner WL. Groshong catheter-associated subclavian venous thrombosis. Am J Med 1993; 95: 419-423
    CrossrefPubMedGoogle Scholar
  • 23 Piwker A, Akeson J, Lindgren S. Complications associated with peripheral or central routes for central venous cannulation. Anesthesia 2012; 67: 65-71
    CrossrefPubMedGoogle Scholar
  • 24 Gallieni M, Pittiruti M, Biffi R. Vascular access in oncology patients. CA Cancer J Clin 2008; 58: 323-346
    CrossrefPubMedGoogle Scholar
  • 25 Eastridge BJ, Lefor AT. Complications of indwelling venous access devices in cancer patients. J Clin Oncol 1995; 13: 233-238
    PubMedGoogle Scholar
  • 26 Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003; 21: 3665-3675
    CrossrefPubMedGoogle Scholar
  • 27 Eisen LA, Narasimhan M, Berger JS et al. Mechanical complications of central venous catheters. J Intensive Care Med 2006; 21: 40-46
    CrossrefPubMedGoogle Scholar
  • 28 Lee AY, Levine MN, Butler G et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol 2006; 24: 1404-1408
    CrossrefPubMedGoogle Scholar
  • 29 Ruesch S, Walder B, Tramer MR. Complications of central venous catheters: Internal jugular versus subclavian access: A systematic review. Crit Care Med 2002; 30: 454-460
    CrossrefPubMedGoogle Scholar
  • 30 Biffi R, Orsi F, Pozzi S et al. Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial. Ann Oncol 2009; 20: 935-940
    CrossrefPubMedGoogle Scholar
  • 31 Merrer J, De Jonghe B, Golliot F et al. Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial. JAMA 2001; 286: 700-707
    CrossrefPubMedGoogle Scholar
  • 32 Timsit JF, Farkas JC, Boyer JM et al. Central vein catheter-related thrombosis in intensive care patients: incidence, risk factors, and relationship with catheter-related sepsis. Chest 1998; 114: 207-213
    CrossrefPubMedGoogle Scholar
  • 33 Mehall JR, Saltzman DA, Jackson RJ et al. Fibrin sheath enhances central venous catheter infection. Crit Care Med 2002; 30: 908-912
    CrossrefPubMedGoogle Scholar
  • 34 van Rooden CJ, Schippers EF, Barge RM et al. Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. J Clin Oncol 2005; 23: 2655-2660
    PubMedGoogle Scholar
  • 35 Blom JW, Doggen CJM, Osanto S et al. Old and new risk factors for upper extremity deep venous thrombosis. J Thromb Haemost 2005; 3: 2471-2478
    CrossrefPubMedGoogle Scholar
  • 36 Barry E, DeAngelo DJ, Neuberg D et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol 2007; 25: 813-819
    CrossrefPubMedGoogle Scholar
  • 37 Palumbo A, Rajkumar SV, Dimopoulos MA et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22: 414-423
    CrossrefPubMedGoogle Scholar
  • 38 Verso M, Agnelli G, Kamphuisen PW et al. Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients. Intern Emerg Med 2008; 3: 117-122
    CrossrefPubMedGoogle Scholar
  • 39 Fijnheer R, Paijmans B, Verdonck LF et al. Factor V Leiden in central venous catheter-associated thrombosis. Br J Haematol 2002; 118: 267-270
    CrossrefPubMedGoogle Scholar
  • 40 Mandala M, Curigliano G, Bucciarelli P et al. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Ann Oncol 2004; 15: 590-593
    CrossrefPubMedGoogle Scholar
  • 41 van Rooden CJ, Rosendaal FR, Meinders AE et al. The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis. Haematologica 2004; 89: 201-206
    PubMedGoogle Scholar
  • 42 De Cicco M, Matovic M, Balestreri L et al. Antithrombin III deficiency as a risk factor for catheter-related central vein thrombosis in cancer. Thromb Res 1995; 78: 127-137
    CrossrefPubMedGoogle Scholar
  • 43 Karabay O, Yetkin U, Onol H. Upper extremity deep vein thrombosis: clinical and treatment characteristics. J Int Med Res 2004; 32: 429-435
    CrossrefPubMedGoogle Scholar
  • 44 Kovacs MJ, Kahn SR, Rodger M et al. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study). J Thromb Haemost 2007; 5: 1650-1653
    CrossrefPubMedGoogle Scholar
  • 45 Prandoni P, Bernardi E, Marchiori A et al. The long term clinical course of acute deep vein thrombosis of the arm: prospective cohort study. Br Med J 2004; 329: 484-485
    CrossrefPubMedGoogle Scholar
  • 46 Rathbun SW, Stoner JA, Whitsett TL. Treatment of upper-extremity deep vein thrombosis. J Thromb Haemost 2011; 9: 1924-1930
    CrossrefPubMedGoogle Scholar
  • 47 Lee AYY, Levine MN, Baker RI et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153
    CrossrefPubMedGoogle Scholar
  • 48 Trujillo-Santos J, Nieto JA, Ruiz-Gamietea A et al. Bleeding complications associated with anticoagulant therapy in patients with cancer. Thromb Res 2010; 125 Suppl 2: S58-S61
    CrossrefPubMedGoogle Scholar
  • 49 Jones MA, Lee DY, Segall JA et al. Characterizing resolution of catheter-associated upper extremity deep venous thrombosis. J Vasc Surg 2010; 51: 108-113
    CrossrefPubMedGoogle Scholar
  • 50 Bauersachs R, Berkowitz SD, Brenner B et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510
    CrossrefPubMedGoogle Scholar
  • 51 Vescia S, Baumgartner AK, Jacobs VR et al. Management of venous port systems in oncology: a review of current evidence. Ann Oncol 2008; 19: 9-15
    PubMedGoogle Scholar
  • 52 Ponec D, Irwin D, Haire WD et al. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a doubleblind placebo-controlled trial – the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol 2001; 12: 951-955
    CrossrefPubMedGoogle Scholar
  • 53 Deitcher SR, Fesen MR, Kiproff PM et al. Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the cardiovascular thrombolytic to open occluded lines trial. J Clin Oncol 2002; 20: 317-324
    CrossrefPubMedGoogle Scholar
  • 54 Sabeti S, Schillinger M, Mlekusch W et al. Treatment of subclavian axillary vein thrombosis: long-term outcome of anticoagulation versus systemic thrombolysis. Thromb Res 2002; 108: 279-285
    CrossrefPubMedGoogle Scholar
  • 55 AbuRahma AF, Short YS, White JF III et al. Treatment alternatives for axillary-subclavian vein thrombosis: long-term follow-up. Cardiovasc Surg 1996; 4: 783-787
    CrossrefPubMedGoogle Scholar
  • 56 Petrakis IE, Katsamouris A, Kafassis E et al. Two Different Therapeutic Modalities in the Treatment of the Upper Extremity Deep Vein Thrombosis: Preliminary Investigation With 20 Case Reports. Int J Angiol 2000; 9: 46-50
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 57 Lokanathan R, Salvian AJ, Chen JC et al. Outcome after thrombolysis and selective thoracic outlet decompression for primary axillary vein thrombosis. J Vasc Surg 2001; 33: 783-788
    CrossrefPubMedGoogle Scholar
  • 58 Attigah N, Hyhlik-Dürr A, Hölper P et al. Die Behandlung der akuten tiefen Bein- und Beckenvenenthrombose durch venöse Thrombektomie und kombinierte endovaskuläre Rekanalisation. Zentralbl Chir 2012; 137: 83-87
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 59 Owens CA, Bui JT, Knuttinen MG et al. Pulmonary embolism from upper extremity deep vein thrombosis and the role of superior vena cava filters: a review of the literature. J Vasc Interv Radiol 2010; 21: 779-787
    CrossrefPubMedGoogle Scholar
  • 60 Usoh F, Hingorani A, Ascher E et al. Long-term follow-up for superior vena cava filter placement. Ann Vasc Surg 2009; 23: 350-354
    CrossrefPubMedGoogle Scholar
  • 61 Boraks P, Seale J, Price J et al. Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies. Br J Haematol 1998; 101: 483-486
    CrossrefPubMedGoogle Scholar
  • 62 Monreal M, Alastrue A, Rull M et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices – prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 1996; 75: 251-253
    PubMedGoogle Scholar
  • 63 Verso M, Agnelli G, Bertoglio S et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 2005; 23: 4057-4062
    CrossrefPubMedGoogle Scholar
  • 64 Niers TM, Di Nisio M, Klerk CP et al. Prevention of catheterrelated venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study. J Thromb Haemost 2007; 5: 1878-1882
    CrossrefPubMedGoogle Scholar
  • 65 Karthaus M, Kretzschmar A, Kroning H et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 2006; 17: 289-296
    PubMedGoogle Scholar
  • 66 Akl EA, Kamath G, Yosuico V et al. Thromboprophylaxis for patients with cancer and central venous catheters: a systematic review and a meta-analysis. Cancer 2008; 112: 2483-2492
    CrossrefPubMedGoogle Scholar
  • 67 Kahn SR, Lim W, Dunn AS et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e195S-e226S
    CrossrefPubMedGoogle Scholar
  • 68 Schallom ME, Prentice D, Sona C et al. Heparin or 0.9 % sodium chloride to maintain central venous catheter patency: a randomized trial. Crit Care Med 2012; 40: 1820-1826
    CrossrefPubMedGoogle Scholar
  • 69 Goode CJ, Titler M, Rakel B et al. A meta-analysis of effects of heparin flush and saline flush: quality and cost implications. Nurs Res 1991; 40: 324-330
    PubMedGoogle Scholar
  • 70 Stephens LC, Haire WD, Tarantolo S et al. Normal saline versus heparin flush for maintaining central venous catheter patency during apheresis collection of peripheral blood stem cells (PBSC). Transfus Sci 1997; 18: 187-193
    CrossrefPubMedGoogle Scholar
  • 71 Kuo YS, Schwartz B, Santiago J et al. How often should a port-A-cath be flushed?. Cancer Invest 2005; 23: 582-585
    CrossrefPubMedGoogle Scholar
  • 72 Hemmelgarn BR, Moist LM, Lok CE et al. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. N Engl J Med 2011; 364: 303-312
    CrossrefPubMedGoogle Scholar
  • 73 Kethireddy S, Safdar N. Urokinase lock or flush solution for prevention of bloodstream infections associated with central venous catheters for chemotherapy: a meta-analysis of prospective randomized trials. J Vasc Access 2008; 9: 51-57
    PubMedGoogle Scholar